Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study

BACKGROUND: Although treatment with imatinib in advanced gastrointestinal stromal tumor (GIST) patients has led to significant clinical benefits, the disease will eventually progress due to imatinib resistance. Treatment options after failure of first-line imatinib include imatinib dose escalation o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Hsu, Jun-Te, Le, Puo-Hsien, Kuo, Chang-Fu, Chiou, Meng-Jiun, Kuo, Chia-Jung, Chen, Tsung-Hsing, Lin, Chun-Jung, Chen, Jen-Shi, Yu, Huang-Pin, Yeh, Chun-Nan, Jan, Yi-Yin, Yeh, Ta-Sen
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Clinical Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5642623/
https://ncbi.nlm.nih.gov/pubmed/29050348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16795
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados